Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice

Investigational New Drugs

Volumn 17, Issue 1, 1999, Pages 29-41

  Van Gijn, R ^a   Van Tellingen, O ^b   Haverkate, E ^a   Kettenes van Den Bosch, J J ^c   Bult, A ^c   Beijnen, J H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CGP 41 251; Metabolism; N benzoylstaurosporine; Pharmacokinetics; Protein kinase C

Indexed keywords

DRUG METABOLITE; MIDOSTAURIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; MICE; MICE, INBRED BALB C; PROTEIN KINASE C; STAUROSPORINE;

EID: 0032823248     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006260217400     Document Type: Article

References (25)

1. Sato W, Yusa K, Naito M, Tsuruo T: Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 173: 1252-1257, 1990
2. Andrejauskas-Buchdunger E, Regenass U: Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41 251. Cancer Res 52: 5353-5358, 1992
3. Fabbro D, Müller M, Meyer T, Regenass U: The PKC inhibitor CGP 41 251 reverses Pgp-mediated multidrug resistance and synergizes with adriamycin. Anti Cancer Drugs 5(suppl 1): 28, 1994
4. Inou M, Kishimoto A, Takai Y, Nishuzuka Y: Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues II. J Biol Chem 252: 7610-7616, 1977
5. Takai Y, Kishimoto A, Inoue M, Nishuzuka Y: Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem 252: 7603-7609, 1977
6. Stryer L, Freeman WH: Biochemistry. Fourth edition. New York, 1995, pp 343-356
7. Lu Z, Hornia A, Jiang YW, Zang Q, Foster DA: Tumor promoting by depleting cells of protein kinase C-delta. Mol Cell Biol 17: 3418-3428, 1997
8. Walker SD, Murray NR, Burns DJ, Fields AP: Protein kinase C chimeras: catalytic domain of alpha beta II protein kinase C contain determinants for isotype specific function. Proc Nat Acad Sci USA 92: 9156-9160, 1995
9. Gescher A: Modulators of signal transduction as cancer chemotherapeutic agents, novel mechanisms and toxicities. Toxicol Lett 82: 159-165, 1995
10. Bradshaw D, Hill CH, Nixon JS, Wilkinson SA: Therapeutic potential of protein kinase C inhibitors. Agents Action 38: 135-147, 1993
11. Basu A, Weixel K, Saijo N: Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ 7: 1507-1512, 1996
12. Cloud-Heflin BA, McMasters RA, Osborn MT, Chambers TC: Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isoenzymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Eur J Biochem 239: 796-804, 1996
13. Bergman PJ, Gravitt KR, O'brian CA: An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate. Cancer Chem Phar 40: 453-456, 1997
14. Zini N, Neri LM, Ognibene A, Scotlandi K, Baldini M, Maraldi NM: Increase of nuclear phosphatidylinositol 4,5-biphosphate and phospholipase C beta 1 is not associated to variations of protein kinase C in multidrug-resistant Saos-2 cells. Microsc Res Tech 36: 172-178, 1997
15. Drew L, Groome N, Warr JR, Rumsby MG: Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for PKC in reducing drug influx. Oncol Res 8: 249-257, 1996
16. Galaforo SS, Berns CM, Erdos G, Corry PM, Lee YJ: Hypoglycemia-induced AP-1 transcription factor and basic fibroblast growth factor gene expression in multidrug resistant human breast carcinoma MCF-7/ADR cells. Mol Chem Biol 155: 163-171, 1996
17. Fine RL, Chambers TC, Sachs CW: P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14: 47-55, 1996
18. Basu A, Evans RW: Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int J Cancer 58: 587-591, 1995
19. Grunicke I, Hofmann J, Utz I, Uberall F: Role of protein kinases in antitumor drug resistance. Oncol Hematol 69: 1-6, 1994
20. Basu A, Weixel K, Saijo N: Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistance human small cell lung carcinoma cells. Cell Growth and Diff 7: 1507-1512, 1996
21. Hunakova L, Sulikova M, Duraj J, Sedlak J, Chorvath B: Stimulation of Ara-C-induced apoptosis in the multidrug-resistant human promyelocytic leukemia cell lines with protein kinase C inhibitors. Neoplasma 43: 291-295, 1996
22. Killion JJ, Beltran P, O'Brian CA, Yoon S, Fan D, Wilson MR, Fidler IJ: The antitumor activity of doxorubicin against drug-resistance murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41 251. Oncol Research 7: 453-459, 1995
23. van Gijn R, van Tellingen O, de Clippeleir JJM, Hillebrand MJX, Boven E, Vermorken JB, ten Bokkel Huinink WW, Schwertz S, Graf P, Beijnen JH: Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 667: 267-276, 1995
24. van Gijn R, Havik E, Boven E, Vermorken JB, ten Bokkel Huinink WW, van Tellingen O, Beijnen JH: High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma. J Pharm Biomed Anal 14: 165-174, 1995
25. Gibaldi M, Perrier D: Pharmacokinetics, 2nd Edition, Marcel Dekker Inc, New York-Basel, 1982